Live Breaking News & Updates on Darren Opland

Stay updated with breaking news from Darren opland. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

AXS-12 statistically significantly reduced cataplexy attacks compared to placebo AXS-12 achieved statistically significant remission of cataplexy compared to placebo AXS-12 statistically. ....

New York , United States , Mark Jacobson , Darren Opland , Michael Thorpy , Axsome Therapeutics Inc , Wake Disorders Center , Corporate Communications , Drug Administration , World Trade Center , Montefiore Medical Center , Cognitive Function , Sleep Wake Disorders Center , Albert Einstein College , Clinician Global Impression , Narcolepsy Symptom Assessment Questionnaire , Epworth Sleepiness Scale , Cognitive Function Items , Functional Outcomes , Sleep Questionnaire , Topline Results , Excessive Daytime Sleepiness , Narcolepsy Overall , Study Evaluating , Mechanistic Approach , Treating Narcolepsy ,

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Total 4Q and full year 2023 net product revenue of $71.5 million and $204.9 million, respectively, representing year-over-year growth of 193% and 309% ....

New York , United States , Joe Oconnor , Barbara Shecter , Goldy Hyder , Darren Opland , Mark Jacobson , Herriot Tabuteau , Gabriel Friedman , World Trade Center , Postmedia Network Inc , Corporate Communications , Axsome Therapeutics Inc , Drug Administration , Development Pipeline , National Post , Blackberry Ltd , Therapeutics Reports Fourth Quarter , Full Year , Provides Business , Joeo Connor , Victoria Wells , Financial Times , Financial Post , New York Times , Axsome Therapeutics ,

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

20.02.2024 - Total 4Q and full year 2023 net product revenue of $71.5 million and $204.9 million, respectively, representing year-over-year growth of 193% and 309% Auvelity 4Q and full year 2023 net product sales of $49.0 million and $130.1 million, . ....

New York , United States , Herriot Tabuteau , Mark Jacobson , Darren Opland , Axsome Therapeutics Inc , Drug Administration , Development Pipeline , World Trade Center , Corporate Communications , Axsome Therapeutics , Chief Executive Officer , Full Year Financial , Digital Centric Commercialization , Breakthrough Therapy , Disease Agitation , New Drug Application , Deficit Hyperactivity Disorder , Depressive Disorder , Eating Disorder , Work Disorder , Trial Topline Results , Trial Initiations ,

Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20

NEW YORK, Jan. 23, 2024 Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced. ....

New York , United States , Darren Opland , Mark Jacobson , Axsome Therapeutics Inc , World Trade Center , Drug Administration , Corporate Communications , Axsome Therapeutics ,

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

Preliminary total 4Q and full year 2023 net product revenue of $71 million and $204 million, respectively Auvelity preliminary 4Q and full year 2023 net product sales of $49 million and $130 million,. ....

New York , United States , Darren Opland , Herriot Tabuteau , Mark Jacobson , Corporate Communications , Sk Biopharmaceuticals Co Ltd , Us Drug Enforcement Agency On , Drug Administration , Development Pipeline Anticipated Milestones , World Trade Center , Axsome Therapeutics Inc , Chief Executive Officer , Fourth Quarter , Full Year , Product Revenue , Pipeline Anticipated , Trial Topline Results , Trial Initiations , Breakthrough Therapy , Prescribing Information , Boxed Warning , Enforcement Agency , Full Prescribing Information , Medication Guide , Axsome Therapeutics ,